Zymeworks reported a significant increase in revenue to $27.1 million for Q1 2025, up from $10.0 million in Q1 2024, primarily due to milestone payments from GSK and Daiichi Sankyo. The company also reduced its net loss to $22.6 million from $31.7 million in the prior year. Cash resources stood at $321.6 million, providing a projected cash runway into the second half of 2027.

Zymeworks reported a revenue of $16.0 million for the third quarter of 2024, a decrease from $16.5 million in the same period last year. The company's net loss for the quarter was $29.85 million, compared to $28.687 million in Q3 2023. Key highlights include the first patient dosed in a Phase 1 trial for ZW171, preclinical data presentations for ZW220 and ZW251, and the completion of an initial share repurchase program.

Zymeworks reported a net loss of $37.686 million for Q2 2024, an improvement from the $51.152 million loss in Q2 2023. Revenue from research and development collaborations was $19.243 million, significantly up from $7.002 million in the prior year. The company ended the quarter with $395.9 million in cash resources, projecting a cash runway into the second half of 2027.

Zymeworks reported a net loss of $31.7 million for the first quarter of 2024, an increase from $24.4 million in the same period last year. Revenue decreased to $10.0 million from $35.6 million in Q1 2023, primarily due to the transfer of responsibility for certain clinical trials to Jazz Pharmaceuticals. Despite the increased net loss, the company maintains a strong cash position of $420.5 million, projecting a cash runway into the second half of 2027.

Zymeworks Inc. reported a substantial increase in revenue for the fourth quarter and full year 2022, primarily due to a significant licensing agreement with Jazz Pharmaceuticals. The company achieved net income for the year, a significant improvement from a net loss in the previous year, and ended 2022 with a strong cash position, extending its cash runway through 2026.